Ken Powell
Europe, England, United Kingdom, London'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
Description
Prior to his current role, Ken had very extensive experience of the Biotechnology sector. In reverse order he was: Executive Chairman of Q-C...
Investor Profile
Ken Powell has backed more than 1 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 1 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series C rounds (top funding stages).
- Majority of deals are located in United Kingdom.
- Strong thematic focus on Biotechnology, Life Science, Therapeutics.
Stage Focus
- Series C (100%)
Country Focus
- United Kingdom (100%)
Industry Focus
- Biotechnology
- Life Science
- Therapeutics
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
'/%3e%3cuse xlink:href='%23a' transform='rotate(-90)'/%3e%3cuse xlink:href='%23a' transform='rotate(180)'/%3e%3c/svg%3e)
